humanin: the mitochondrial-derived peptide and what longevity research shows

humanin is a 24-amino-acid peptide encoded inside the mitochondrial 16S ribosomal RNA gene (MT-RNR2). it was discovered in 2001 in the surviving neurons of an Alzheimer's brain and has since become the founding member of a small family of mitochondrial-derived peptides studied for their role in cellular stress responses, metabolic health, and biological aging.

what is humanin?

humanin is a short peptide whose coding sequence sits inside a mitochondrial ribosomal RNA gene rather than the nuclear genome. it is part of a family called mitochondrial-derived peptides (MDPs), which the cell uses as stress signals from the mitochondrion to the rest of the body.

the original report came from Hashimoto and colleagues in 2001, who isolated humanin from the occipital cortex of a patient with Alzheimer's disease and showed that it protected cultured neurons from amyloid-beta toxicity [1]. the peptide is 24 amino acids long in humans and is encoded inside the mitochondrial 16S rRNA gene (MT-RNR2). a single open reading frame buried inside a ribosomal RNA gene was unusual enough that some early reviewers questioned whether the peptide was real before independent groups confirmed it in serum and tissue.

a stabilized synthetic analog, HNG (humanin S14G), substitutes glycine for serine at position 14 and is roughly a thousand-fold more potent in cellular assays. most of the preclinical literature on humanin uses HNG or another stabilized analog rather than the native sequence.

how does it signal?

humanin acts as an extracellular signaling peptide. it engages a receptor complex on the cell surface and binds intracellular partners such as IGFBP-3 and Bax that together drive its anti-apoptotic and metabolic effects.

outside the cell, humanin binds a trimeric receptor made up of CNTFR, WSX1, and gp130, and separately engages FPRL1 (formyl peptide receptor-like 1, also called FPR2) [2]. downstream signaling runs through STAT3, ERK, and AKT, which is how the peptide pushes cells toward survival rather than apoptosis.

inside the cell, humanin physically binds the pro-apoptotic protein Bax and prevents it from moving to the mitochondrial outer membrane, which blunts cytochrome-c release and the intrinsic apoptosis pathway [3]. it also binds IGFBP-3, which couples it to the insulin and IGF-1 signaling axes that have been a major focus of aging research for two decades.

what does the longevity and metabolic evidence show?

the strongest human signal so far is that circulating humanin levels fall with age and that long-lived people and their offspring tend to have higher levels. animal data point in a similar direction. no controlled human trial has tested whether raising humanin extends lifespan or healthspan.

Muzumdar, Cohen and colleagues showed that circulating humanin declines roughly linearly with chronological age in humans and that Ames dwarf mice (a long-lived strain with reduced GH/IGF-1 signaling) maintain higher humanin levels than wild-type controls [4]. a separate study reported that centenarians and their offspring carry higher circulating humanin than age-matched controls, which is the kind of human association that motivates the longevity framing even though it does not establish cause [5].

on the metabolic side, intracerebroventricular humanin in rats improved insulin sensitivity through hypothalamic signaling, and peripheral administration of HNG protected against streptozotocin-induced diabetes in mouse models [6]. cardiovascular work has shown that humanin and HNG reduce infarct size in rodent models of ischemia-reperfusion injury and oppose endothelial apoptosis in cell culture [7]. these are the kinds of mechanistic results that justify continued interest, but they are mouse and cell data, not clinical evidence.

on the neurological side, the original Alzheimer's framing has been extended by groups showing that HNG protects cultured neurons from a range of insults and reduces amyloid-beta plaque burden in transgenic mouse models. no controlled clinical trial has tested humanin or HNG in patients with Alzheimer's disease or any other neurodegenerative condition.

regulatory status

humanin and HNG are research compounds. no humanin product is approved by the FDA, EMA, or any other major regulator. there are no published Phase 1 trials in healthy adults and no human safety or pharmacokinetic dataset of the kind required to support clinical use.

humanin is sold by some research peptide suppliers as a reagent for in vitro work. that is not the same as being a medicine. there is no approved manufacturing standard, no validated potency assay for the products sold outside the research supply chain, and no regulated quality control on identity or purity. the practical takeaway: humanin is interesting longevity science, but anyone reading about it should keep the gap between cell-and-mouse data and clinical use front of mind.

where it fits among research peptides

humanin sits in a small family of mitochondrial-derived peptides that includes MOTS-c and the SHLPs. together they are part of a wider research conversation about how mitochondrial function shapes whole-body aging. the family is mechanistically distinct from the GH-axis peptides and from peptide bioregulators.

the closest comparison is MOTS-c, the other mitochondrial-derived peptide with substantial preclinical evidence. MOTS-c is encoded in the 12S rRNA gene and acts mainly as an AMPK activator with effects on glucose handling and exercise capacity, while humanin is encoded in the 16S rRNA gene and runs through anti-apoptotic and IGFBP-3 pathways. the two are often discussed together because both emerge from mitochondrial DNA and both decline with age, but their downstream biology is different.

a separate comparison is with peptide bioregulators such as epitalon, which are sometimes marketed under similar "longevity peptide" framing. the evidence quality is very different: humanin has Western mechanistic literature in NEJM-adjacent journals, while the bioregulator literature is dominated by Russian-language reports of mixed methodology. for a broader map of how peptides interact with the cellular machinery of aging, the underlying biology is covered in our free peptides and your body module.